paclitaxel has been researched along with Encapsulating Peritoneal Sclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carvalho, PO; Costalonga, EC; Maranhão, RC; Noronha, IL; Pepineli, R; Silva, FMO | 1 |
| Blomfield, P; Bohmer, R; Chan, WS; McIntosh, R | 1 |
2 other study(ies) available for paclitaxel and Encapsulating Peritoneal Sclerosis
| Article | Year |
|---|---|
Use of paclitaxel carried in solid lipid nanoparticles to prevent peritoneal fibrosis in rats.
Topics: Animals; Disease Models, Animal; Female; Liposomes; Male; Nanoparticles; Paclitaxel; Peritoneal Fibrosis; Peritoneum; Rats; Rats, Wistar; Transforming Growth Factor beta | 2022 |
Peritoneal fibrosis leading to small bowel obstruction two years after first-line intraperitoneal chemotherapy for optimally debulked ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisplatin; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Intestinal Obstruction; Intestine, Small; Liver Neoplasms; Membrane Proteins; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Fibrosis; Treatment Outcome | 2011 |